Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials
American Journal of Hypertension, 04/21/2011
Gao D et al. - Aliskiren is as effective as angiotensin receptor blockers (ARBs) (losartan, valsartan, and irbesartan) in controlling blood pressure (BP) and does not differ from ARBs in risk of adverse events.
Reports of randomized controlled trials (RCTs) comparing aliskiren and ARBs in patients with hypertension were selected by a search of the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE.
The main outcome measures were reduction in diastolic BP (DBP) and systolic BP (SBP) and rates of therapeutic response and BP control.
The authors also compared the tolerability of aliskiren and ARBs.
Revman v5.0 was used to obtain the pooled estimates.
The authors analyzed data from 10 reports of trials involving 3,732 participants.
DBP and SBP reduction did not differ between aliskiren and ARBs (weighted mean difference (WMD), -0.18; 95% confidence interval (CI), -1.07 to 0.71, and WMD, 0.15; 95% CI, -1.38 to 1.69, respectively).
Aliskiren and ARB treatment did not differ in rates of BP control or therapeutic response.
Moreover, aliskiren and ARB treatment led to a similar number of adverse events, severe adverse events, and withdrawal due to adverse events.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.